OncoMatch/Clinical Trials/NCT06247605
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
Is NCT06247605 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies AL8326 tablets for small cell lung carcinoma.
Treatment: AL8326 tablets — This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
including first-line platinum-based therapy
Cannot have received: (AL8326)
Having previously used AL8326 tablets
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L (1500/mm3), platelets ≥ 80 × 10^9/L, hemoglobin ≥ 9.0 g/dL
Kidney function
Serum creatinine ≤ 1.5 × ULN and estimated creatinine clearance rate ≥ 60 ml/min by Cockcroft-Gault formula
Liver function
serum total bilirubin ≤ 1.5 × ULN (except Gilbert's syndrome); ALT and AST ≤ 2.5 × ULN (no liver mets), ≤ 5 × ULN (with liver mets)
Cardiac function
Left ventricular ejection fraction (LVEF) > 50% at screening
adequate organ and bone marrow function and meets the following laboratory criteria: ... see details above
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify